Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CALCITONIN (SALMON SYNTHETIC)

All injection strengths: listing conditions apply

Calcitonin Salmon Injection, USP · PIN 09858397 · 200IU/mL · injection solution-2mL vial (With Preservative)

Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Calcitonin Salmon Injection, USP · DIN 09858397 Manufacturer: Hikma Pharmaceuticals USA Inc.; listing date 2026-08-31 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Calcitonin Salmon Injection, USP: Formulary list price $57.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $57.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858397)

Source record
DIN 09858397: Calcitonin Salmon Injection, USP Raw flags: sec3c=Y Item: 682400016; group id 787; item number 1917; lccId None; manufacturer id HKP Source form: Inj Sol-2mL Vial Pk (With Preservative); strength: 200IU/mL Recorded listing: Temporary benefit (shortage substitute) Source prices (unrounded): $57.0000; ministry $57.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858397 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:24 Parathyroid Agents) and how they are covered

Matched class: 68:24 Parathyroid Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 68:24 Parathyroid Agents

TERIPARATIDE

· 4 products · Limited Use, codes 676 (3), Limited Use, codes 635 (1) · strengths: 250mcg/mL · Inj Sol-2.4mL Pref Pen, Inj Sol-3mL Cart Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:24
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS 1. Paget's Disease: Treatment of symptomatic Paget's disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable. 2. Hypercalcemia: Early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin may be used in patients with azotemia and those with limited cardiac reserve in whom intravenous fluids may be contraindicated. Due to evidence of an increased risk of malignancies with the long term calcitonin use, the treatment duration should be limited to the shortest period of time possible and using the minimum effective dose. 2 https://pdf.hres.ca/dpd_pm/00057227.PDF PM date: June 3, 2020 Source product: CALCIMAR; DIN 01926691; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.